PharmaJet, Inc., a developer of needle-free injection technology, has closed a Series C round of financing.

PharmaJet’s needle-free injection technology delivers liquid drugs and vaccines to intramuscular, subcutaneous and intradermal tissue depths. PharmaJet injectors use pressure to create a fine stream of liquid that penetrates the skin, delivering doses to the desired depth, while eliminating needle-stick risk and the burden of sharps waste management.

PharmaJet’s investors include Hearthstone Investments, Kulik Investments, Baring Communications Equity (Emerging Europe) Limited, and private investors.

A Denver-based company, PharmaJet opened an office in Baltimore at the University of Maryland BioPark in April 2010.

SOURCE: Posted by TechNews on December 14, 2011.